{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-069381","form_type":"8-K","ticker":"LITS","cik":"0001262104","company_name":"Lite Strategy, Inc.","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.481835+00:00","generated_at":"2026-06-07T14:44:11.943218+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MEI Pharma reports clinical data on oral CDK9 inhibitor voruciclib at ASH2023; safety profile well-tolerated","bullets":["Voruciclib monotherapy up to 200 mg on intermittent schedule well-tolerated; no DLTs. Common AEs: diarrhea, nausea, anemia, fatigue.","On-target Mcl-1 and RNA Pol II p-S2 reductions demonstrated in correlative pharmacodynamic studies.","In AML monotherapy: 1 patient achieved morphologic leukemia-free state; 9 had stable disease (2 for ≥3 months).","In B-cell malignancies: 4 patients had stable disease with tumor size decrease.","Combination with venetoclax ongoing; no DLTs or overlapping toxicity; anti-tumor activity observed with multiple patients on therapy ≥4 months."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-069381","json":"https://secwatch.observer/filing/0000950170-23-069381.json","markdown":"https://secwatch.observer/filing/0000950170-23-069381.md","text":"https://secwatch.observer/filing/0000950170-23-069381.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1262104/000095017023069381/0000950170-23-069381-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1262104/000095017023069381/meip-20231211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:44:11.943218+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}